心脏性休克并发症周周心肌病症从levosimendan和bromocriptine的联合治疗中受益
Tobias J Pfeffer1, Faramarz Matinmehr2, Ante Radocaj2
1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
European journal of heart failure
|March 2, 2026
概括
单独使用levosimendan (LS) 可能会通过增加益生素 (PRL) 和PAI-1来加剧周周心肌病 (PPCM). 结合LS与布罗莫克里普丁 (BR) 改善了心脏功能和PPCM患者心脏性休克 (CS) 的存活率.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 产周心肌病 (PPCM) 涉及左心室缩功能障碍,由等离子体激活剂-抑制剂1 (PAI-1) 和16K-益生菌素 (PRL) 驱动.
- 在PPCM中治疗心脏性休克 (CS) 是一个挑战,关于levosimendan (LS) 安全性和有效性的数据有限.
研究的目的:
- 在PPCM小鼠模型和人类患者中研究LS的分子效应和安全性.
- 为了评估LS和布罗莫克里普丁 (BR) 的组合疗法,用于CS的PPCM.
主要方法:
- 使用心肌细胞特异性STAT3淘汰 (CKO) 鼠标模型进行PPCM.
- 在小鼠中分析了PAI-1表达,纤维化,毛细血管密度和死亡率.
- 追溯研究了来自德国PPCM注册表的LS和BR治疗的17名PCM患者.
主要成果:
- 仅LS就会在PPCM小鼠模型中恶化心力衰竭,纤维化和死亡率.
- 与BR结合的LS在小鼠中保留了心脏功能,并阻止了LS诱导的PAI-1上调.
- 所有17名用LS和BR治疗的CS的PPCM患者都在急性阶段幸存下来,并观察到显著的心脏恢复.
结论:
- 与LS和BR的组合疗法对于患有CS的PPCM患者来说似乎是安全的,并且可能有益.
- 在PPCM与CS中的LS单疗可能通过PRL/PAI-1通路加剧心脏功能障碍.
- 在PCM患者中,BR应伴随LS治疗,以减轻CS的不良影响.
关键词:
布罗莫克里普提因 (bromocriptine) 是一种蛋白质.心脏发生的冲击是心脏的冲击.心脏衰竭是因为心脏衰竭.您的位置 首页 您的位置产前心肌病 产前心肌病 产前心肌病血小板蛋白质 (Thrombospondin) 是一种血小板蛋白质.更多相关视频
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
2.8K
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.3K
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.7K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.7K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
798
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
798
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
810
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
810
01:29Cardiomyopathy V: Interprofessional Care
761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
461
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
461